4. Bacteriological and immunological techniques have rarely been used to demonstrate the absence of intercurrent streptococcal infections, in order to prove that the recurrent inflammation was a post-therapeutic rebound rather than a new attack of rheumatic fever.
As a result of these inconsistencies, the rheumatic-fever rebound phenomenon has been poorly understood and has received various interpretations. It has been attributed to (i) polycyclic rheumatic fever ,(ii) withdrawal of treatment before the natural course of inflammation had subsided, (iii) relative adrenal insufficiency, or (iv) the accumulated rheumatic inflammation whose clinical outlet had been prevented by the preceding suppressive treatment. The relative importance of these four possible causes is uncertain.
The present survey has studied the incidence and significance of the rebound phenomenon in the attacks of acute rheumatic fever in 265 children and adolescents, treated with a variety of agents and followed throughout the convalescent period and beyond. The results help clarify the nature of the rebound process and have clinical and conceptual implications for the natural history and management of rheumatic activity.
CLINICAL MATERIAL AND METHODS OF STUDY
The patients were drawn from 331 consecutive admissions to Irvington House during the 26-month period beginning 1 July 1956 . Of these patients, 44 had not had rheumatic fever and 22 had illnesses which had been originally labeled rheumatic fever but which did not fulfill the modified Jones criteria2 for this diagnosis. The remaining 265 patients all had had unequivocal attacks of rheumatic fever and constitute the subjects of this report.
They were admitted to Irvington House at different phases of the acute rheumatic attack and in different stages of various kinds of anti-inflammatory therapy. Some arrived early in the attack while receiving no treatment or full doses of antiinflammatory drugs, while others were sent purely for convalescence after all therapy had been stopped.
The routine management at Irvington House was as follows: Rectal temperature and "sleeping" pulse rate were measured daily. The uncorrected* (Wintrobe) erythrocyte sedimentation rate and serum C-reactive protein were tested at weekly intervals for at least eight weeks after both of these acute phase reactants had become and remained normal following cessation of anti-inflammatory therapy. All patients received continuous oral or parenteral prophylaxis** against streptococcal infections. These Rebound in acute rheuumatic fever I FEINSTEIN, SPAGNUOLO, GILL infections were sought by bacteriological and serological techniques. Throat cultures were taken for three consecutive days after admission and repeated thereafter when clinically indicated. The anti-streptolysin 0 titer was measured on admission and at monthly intervals until discharge. When there was clinical, bacteriological, or serological suspicion of streptococcal infections, consecutive sera were simultaneously tested for anti-streptolysin 0, antistreptokinase, and anti-hyaluronidase titers.'7 Periodic dental examinations and appropriate local dental therapy helped maintain asepsis of the teeth and gums and removed dental inflammation as a potential cause10 of fever and infection.
Since the patients came from many different sources, their initial therapeutic management was varied and could not be statistically randomized. After they reached Irvington House, the subsequent treatment depended on their clinical status and laboratory tests. When uncontrolled rheumatic activity was present, medication was begun or altered until the inflammation was suppressed. When the disease was under therapeutic control, the dosage of the anti-inflammatory agent was gradually lowered and discontinued after varying lengths of time, depending on the nature and duration of previous treatment and the condition of the patient. 4 . The appearance of diastolic murmurs or of pericardial friction rubs, when these were unequivocal and were clearly new developments. 5 . The development of congestive heart failure.
6. The appearance of nodules or erythema marginatum.
The pulse rate measurements were taken while the patients were asleep, to ensure that tachycardia was not due to psychic stimulation. The occurrence or reappearance of chorea was not listed as a specific manifestation of rheumatic activity, because the precise time of onset or cessation of choreic movements is difficult to determine, and because they often occur as a late manifestation of the same initial attack."'19 Prolongation of the P-R interval was omitted from these parameters of rheumatic activity because of difficulties in its accurate graphic measurement," uncertainties about the range of normality permitted at different cardiac rates,' the absence of correlations between its prolongation and other features of carditis,' and finally, because it sometimes remains permanently prolonged without relation to the rheumatic course.'
Using the above criteria for rheumatic activity, the following classification of rebounds could be made: started, and was continued beyond the cessation of salicylate therapy. The remaining 13 patients in the "combined" group received the two drugs sequentially or concomitantly in a variety of patterns. A rebound was associated with "combined" therapy only if the patient had previously received both types of treatment. For classification of the intial clinical status, the patients were divided as follows: Those with "no valvular involvement" had had only arthritis or chorea but lacked the diastolic murmurs or significant apical systolic murmurs which characterized those with "valvular involvement."2'5 The distinction between physiological and pathological apical systolic murmurs was made according to previously described criteria of loudness, length, and location. " In the group with valvular involvement, patients with significant heart enlargement (i.e., at least one chamber 2+ enlarged) were separated from those with no or slight cardiomegaly. 2. There were 43 slight and 53 significant laboratory rebounds. They occurred even in patients who had received no anti-inflammatory therapy, appearing in more than one third (12/34) of the "untreated" group.
3. Of the 12 "untreated" patients with laboratory rebounds, 5 had no heart disease and 7 had valvular involvement without significant cardiomegaly. These rebounds occurred: during early ambulation after strict bedrest (in 4); in the first two weeks after transfer to the ambulatory unit (in 5); beyond two weeks after transfer to the ambulatory unit (in 3). Since the progression to ambulation was often made as soon as the acute phase reactants reached normal values, it is to be expected that some elevations in these values would occur spontaneously while the patients were ambulatory. These data therefore do not permit the conclusion that the laboratory rebounds in this group necessarily were due to the ambulation.
4. There were 8 slight and 41 significant clinical rebounds. In patients who received suppressive treatment, clinical rebounds occurred with the following frequency: salicylates, 9 per cent (10/106); steroid, 34 per cent (26/77); and combined treatment, 27 per cent (13/48) . No clinical rebounds occurred in the untreated patients. These data indicate that a laboratory or clinical rebound (as herein defined) is a common event in acute rheumatic fever, occurring in more than half of the patients in this survey. Laboratory rebounds occurred even in patients who received no anti-inflammatory therapy; clinical rebounds occurred only in patients who received anti-inflammatory therapy and were significantly more frequent in those whose treatment included steroids than in those who received salicylate alone, (X2 = 13.4; p < 0.01).
Types of treatment and relation to clinical status of patients (Table 2) In patients with little or no cardiac damage, salicylates alone were used as frequently as steroids and combined therapy. In patients with significant cardiomegaly, the number who received steroid and combined treatment was almost three times as great as those who were given aspirin alone. The greater use of steroids in the latter group of patients may be due to two fea-tures. First, many physicians continue to prefer steroids for acutely ill patients with significant heart disease even when no cardiac failure is present. Secondly, when it was believed that carditis was not adequately controlled by salicylates alone, steroids were added to the treatment. In this situation the patient's therapy would be classified in the steroid or combined group.
Types of rebound and relation to clinical status of patients ( .01) and suggest that an increase in the severity of heart disease predisposes to an increased incidence of clinical rebound. However, as Table 2 indicates, steroid treatment was used more often in patients with severe heart disease, and the higher incidence of clinical rebounds in this group might possibly be related to the therapy rather than to the cardiac status. This possibility is explored in Table 4 , below.
* For this and subsequent tables, the designation "laboratory" and "clinical" rebounds combines the "slight" and "significant" sub-groups of each category.
Types of rebounds and relation to clinical status and preceding treatment (Table 4) In patients with no valvular involvement, a clinical rebound occurred in 6 per cent of those treated with salicylate, in 18 per cent of the steroid group, and in 32 per cent of those who received combined therapy. For these patients, the lower incidence of clinical rebounds after salicylates as compared to steroids and combined therapy is statistically significant (X2 4.75, p <0.05). In patients with evidence of valvular disease but without significant cardiomegaly, a clinical rebound occurred in the treatment groups (Table 5) The after-effects of therapy may be influenced by its dosage and duration. In considering the relation of these variables to subsequent rebounds, only the salicylate and steroid groups could be analyzed because "combined" 267 Agent therapy had been given in too many different ways to permit detailed classification. The occurrence of rebounds was tabulated in both the steroid and salicylate groups with regard to total dosage of the agent (sum of the daily doses) and the total duration of treatment. In addition, treatment in salicylate patients was classified, using body weight, into units of total dosage per pound. No striking correlations emerged with either agent, from a consideration either of total dosage or of total dosage per pound. The data on duration of treatment seemed to be more significant and are listed in Table 5 . In patients who received salicyates, clinical rebounds occurred, Table 4 ) were increasingly likely as the severity of heart disease was increased. These results indicate that steroid treatment, given for more than 8 weeks, was associated with clinical rebounds in more than half of the patients, particularly in those with more severe cardiac damage. Salicylate treatment maintained for longer than 8 weeks appeared to prevent clinical rebounds, regardless of cardiac status, but the present survey included only 2 patients with significant cardiomegaly who received salicylate alone for over 8 weeks. Clinical rebounds in patients in this category have been noted previously at Irvington House and elsewhere, and the present data do not imply that rebounds will always be prevented by long-term salicylate treatment.
Relation of clinical rebounds to age and sex (Table 6) Clinical rebounds occurred in 35 (22 per cent) of the 161 boys in this series, and in 14 (13 per cent) of the 104 girls. Despite the tendency of steroids to produce striae, acne, and other cutaneous changes, hormonal Time interval between end of treatment and occurrence of rebounds (Table 7) In patients with laboratory rebounds, the abnormal acute phase reactants appeared sporadically following their original return to normal levels. Although more laboratory rebounds occurred during the first week than at any other time after cessation of therapy, they also occurred in appreciable frequency at subsequent periods. Of the laboratory rebounds, 86 per cent had occurred by the end of eight weeks while 14 per cent took place beyond eight weeks. In contrast, most (80 per cent; 39/49) of the clinical rebounds occurred while therapy was being tapered or during the first week after it was stopped. No clinical rebound occurred eight weeks or more after therapy was stopped. Thus, patients who did not have a clinical rebound within a week or two after cessation of therapy were likely to complete their course without having one, and would not have one after eight weeks. On the other hand, elevations of acute phase reactants (a laboratory rebound) could occur anytime within the first two post-therapeutic months and appeared even later in 14 per cent of patients.
Features and sequelae of the rebounds Figures 1 and 2 illustrate the sequence of events in two patients with clinical rebounds. It is of interest that laboratory rebounds subsided spontaneously in all cases and had no subsequent clinical effects. The details of the events, management, and sequelae of clinical rebounds are described separately. ' It should be noted that the incidence of clinical rebounds and of individual events within them is somewhat less in the present series than in those reported previously. Some of these differences are probably due to the criteria used to define the rebound, and the demand in the present study that values for acute phase reactants had to have achieved normal limits before the reappearance of abnormal features could be considered a true rebound. arranged plan. This same circumstance in the current survey, however, is advantageous because it provides the opportunity to compare the results of various therapeutic agents and the influence of different durations of treatment. These comparisons could not be made in studies where salicylates and/or steroids were given to all patients for the same length of time and where "combined" treatment had not been used. The present work has several other advantages: the patients were in the younger age group where rheumatic fever predominates, their number is several times greater than in any previous reports, an untreated group was available for study, and the rebounds were related to the initial clinical status of the patients. The division of patients into three clinical categories has helped to minimize the effects of nonrandom allocation of therapeutic agents and has enabled the recognition of direct correlations between the cardiac status and the occurrence and types of clinical rebounds.
The results show that rebounds are a common event in acute rheumatic fever; they appear in two ways, each with different consequences. The laboratory rebound consists only of abnormalities in acute phase reactants of the blood. It subsides in all patients without additional therapy and it apparently does not affect the patients' clinical status. By contrast, the clinical rebound is more to be feared because of its acute, and potentially permanent, cardiac effects. Although clinical rebounds did not bring carditis to patients who did not have it initially, they did produce significant new cardiac manifestations in some of those who had previously shown evidence of valvular involvement. The laboratory rebounds were unrelated to clinical status and preceding therapy; they could be found even in untreated patients. The clinical rebounds were more frequent with increasing severity of heart disease, and occurred only in patients who had received anti-inflammatory therapy; they were particularly common after treatment with steroids.
The implications of these data can be applied to a number of basic and clinical problems in rheumatic fever. Some of these will be considered separately.'6 The remainder of the discussion here will be devoted to possible mechanisms of the rebound phenomenon.
The clinical rebound patterns observed in this survey cannot be well explained by any of the three possible causes to which this phenomenon is usually attributed. Polycyclic rheumatic fever' is unlikely because the incidence of rebounds is far higher than the natural occurrence of multiple rheumatic cycles and because the rebounds occur too close to the time of reduction or cessation of therapy. The persistence of rheumatic activity due to premature withdrawal of treatment6 does not seem a valid explanation because so many rebounds occur after extremely long therapeutic courses. Relative adrenal insufficiency' does not account for the rebounds which follow salicylate treatment, and hypoadrenalism has seldom been demonstrable in rebounds after steroid treatment.' Moreover, none of these mechanisms would account for the increased incidence of clinical rebounds as the severity of cardiac damage increases. An attractive explanation which fits the observed data is provided by a new hypothesis, which may conveniently be called "suppressed inflammation." This theory assumes that the average attack of rheumatic fever creates a fixed amount of inflammation which must be dissipated. The amount of inflammation will differ in different patients. Its total quantity will determine the severity of the clinical features. The rapidity with which it appears will determine the peak of its intensity and the rapidity with which it dissipates will determine the duration of the attack. Anti-inflammatory therapy will suppress the appearance and dissipation of the inflammation. The suppression can be total or partial, depending on the amount of inflammation and the therapy employed.
If the suppression is total, as with full doses of steroids, the inflammation remains dormant and accumulates until the therapy is reduced or stopped. At that time, the amount of residual inflammation and the rapidity of its appearance will determine whether the resultant flare-up of rheumatic activity is more or less severe than the original attack. Longer periods of totally suppressive therapy will result in greater quantities of residual inflammation and hence greater likelihood of post-therapeutic clinical rebounds.
If the suppression is partial, as with salicylates, some inflammation can continue to dissipate during the period of treatment although the amount of inflammation which appears may not be great enough to create clinical symptoms. In this situation, longer durations of therapy would be desirable since less residual inflammation is likely to remain when the therapy is stopped. Figure 3 (A-F) shows hypothetical clinical situations to illustrate the data and the theory derived from them. The course of rheumatic fever in a typical untreated patient is shown in A. The inflammation first rises to the level of clinical abnormalities, then drops to the level of only laboratory abnormalities and finally reaches normal levels. Drawing B shows how this course would be influenced by a long period of steroid treatment. The dotted line shows the natural course of the untreated disease, and the solid line shows the effect of the therapy. The steroids suppress inflammation promptly and profoundly. The undispersed inflammation is shown in the dotted area. When the steroids are stopped, this inflammation erupts and a clinical rebound occurs. A long course of steroid therapy will not always be followed by a clinical rebound, because the original amount of inflammation may have been small, or because some dissipation of inflammation may occur during the long "tapering" period at gradually lowered dosage. During the latter interval, incomplete suppression of inflammation may allow enough sub-clinical dispersion so that the cessation of treatment will be followed by a mild rebound or none. Figure C shows Figure D shows the effect of the less potent salicylates. These can only suppress inflammation partially to the level of laboratory abnormalities. This may not achieve ideal results in tests of acute phase reactants, but it allows the expression of considerable amounts of inflammation at a subclinical level. If the salicylate is continued for a long time, enough inflammation may dissipate during the treatment so that the post-therapeutic remainder is small enough to create little or no rebound. With a shorter course of salicylate, as in E, the residual inflammation resumes its appearance at a higher level of disease activity, so that the rebounds may reach clinical levels of severity.
These observations will explain why an appropriate form of combined therapy may reduce the severity of clinical rebounds. With steroid treatment the suppressed inflammation accumulates as shown in the dotted area of F. During this period, the suppressant effect of salicylates appears superfluous. When the steroids are lowered and stopped, however, the dispersion of inflammation resumes. The presence of salicylates at this time will not prevent the flare-up from occurring but will help regulate its severity as may be seen in comparison with Figure B .
The above conjectures obviously do not account for all aspects of rheumatic activity, but appear to offer a satisfactory explanation for most of the observed clinical rebound phenomena.
SUMMARY
The rebound phenomenon has been studied in 265 children and adolescents consecutively admitted to Irvington House during the acute or convalescent phases of unequivocal attacks of rheumatic fever. In each patient the analysis included a sustained chronological account of the illness from its onset to the end of convalescence. The patients were classified according to their initial cardiac status and the anti-inflammatory treatment which had been given. The rebound was defined as the reappearance, after initial subsidence, of clinical and/or laboratory manifestations of rheumatic activity, in the absence of an intervening streptococcal infection.
Laboratory rebounds were defined as the recurrence of abnormal values only in the erythrocyte sedimentation rate or serum C-reactive protein.
They appeared in 96 patients and all subsided spontaneously without any evident adverse clinical effects. Their incidence did not seem related to the clinical status or to the nature of the preceding treatment and they also occurred spontaneously in patients who received no suppressive treatment. In treated patients, they appeared at varying intervals after therapy was stopped and 14 per cent occurred later than 8 weeks.
A who did not, and was particularly common in those with significant cardiac enlargement. There were no clinical rebounds in patients who received no anti-inflammatory therapy. In patients who received suppressive therapy, clinical rebounds were more prevalent in those given steroids or combined steroid-salicylate treatment than in those treated with salicylate alone. In the salicylate-treated group, the incidence of clinical rebounds was unrelated to cardiac status and they occurred exclusively in those patients who received therapy for less than 8 weeks. In the group treated with steroids the incidence of clinical rebounds increased markedly as the duration of treatment increased and was particularly high in patients with substantial initial cardiac damage. "Combined" therapy was associated with approximately the same incidence of clinical rebounds as steroid treatment alone, but the rebounds seemed less severe.
Of the various hypotheses which have been advanced for the pathogenesis of most clinical rebound phenomena, the most satisfactory explanation appears to be that suppressive medication prevents the dispersion of rheumatic inflammation and that the accumulated residual inflammation then appears in the form of a rebound when the suppression is reduced or stopped. The severity of the rebound will depend upon how much inflammation was present initially, how much of it was suppressed by the therapy, and how much remains afterwards.
